Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766141 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL6548512 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL11528188 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL29118750 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL2723206 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL15445144 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL2360071 | 0.98 | — | — | |
| SCHEMBL1142610 | 0.90 | — | — | |
| SCHEMBL2706386 | 0.90 | MEN1 (0.53) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL766061 | 0.87 | TSHR (0.56) | TSHRMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-11389466-B2 | Multivalent fucose derivatives for use as a drug | UNIVERSITE DE NANTES (FR) | 2022-07-19 | — | — | US | disclosed |
| EP-3582789-B1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | UNIV NANTES (FR) | 2022-06-22 | — | — | EP | disclosed |
| US-20200268782-A1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | NANTES UNIVERSITE (FR) | 2020-08-27 | — | — | US | disclosed |
| US-20200268782-A1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | NANTES UNIVERSITE (FR) | 2020-08-27 | — | — | US | disclosed |
| US-4990505-A | Treating asthma, bronchitis; adrenergic stimulants | GLAXO GROUP LIMITED (GB) | 1991-02-05 | — | — | US | disclosed |
| US-4908386-A | Pharmaceuticals | GLAXO GROUP LIMITED (GB) | 1990-03-13 | — | — | US | disclosed |
| EP-0220054-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
| US-3983247-A | 2,4-Dodecadienoic acid esters and use for insecticides | HOFFMANN-LA ROCHE INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389466-B2 | Multivalent fucose derivatives for use as a drug | FUCA2, FUCA1, FUT6 | TSHR 4700/4885GAA 244/4885MEN1 1139/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | TSHR 1160/4885GAA 525/4885MEN1 2796/4885 |
| US-20200268782-A1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | FUCA2, FUCA1, FUT6 | TSHR 4700/4885GAA 244/4885MEN1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.